NasdaqGM:EYPTPharmaceuticals
Is EyePoint’s New Commercial Chief the Missing Piece in the DURAVYU Story for EYPT Investors?
EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, tasking him with leading commercial strategy and launch preparation for DURAVYU, the company’s Phase 3 wet age-related macular degeneration and diabetic macular edema candidate.
Campbell’s long history of building ophthalmology franchises and launching eye-care products at companies such as Genentech, Novartis, Shire, and Opthea could materially shape how EyePoint brings DURAVYU to market.
Now we’ll examine how...